Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab and Numidargistat in Japanese patients with solid tumors
NCT03910530Phase 1Completed
- Sponsor
- Incyte
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of retifanlimab and numidargistat in solid tumor (advanced stage) (4 arms), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events up to 2 years. Started Jul 2019; status: completed.
02
Drugs
retifanlimabnumidargistat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03910530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910530.